Flavin-containing monooxygenase activity in hepatocytes and microsomes: In vitro characterization and in vivo scaling of benzydamine clearance

Drug Metabolism and Disposition

Volumn 30, Issue 10, 2002, Pages 1087-1093

  Fisher, Michael B ^a   Yoon, Kwansik ^a   Vaughn, Marcie L ^a   Strelevitz, Timothy J ^a   Foti, Robert S ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYDAMINE; DIMETHYLANILINE MONOOXYGENASE; XENOBIOTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; DRUG CLEARANCE; DRUG OXIDATION; DRUG TRANSFORMATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIVER CELL; LIVER MICROSOME; MALE; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RAT;

ANIMALS; BENZYDAMINE; BIOTRANSFORMATION; DOGS; ENZYME ACTIVATION; HEPATOCYTES; HUMANS; MACACA FASCICULARIS; METABOLIC CLEARANCE RATE; MICE; MICROSOMES, LIVER; OXYGENASES; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA;

EID: 0036784485     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.10.1087     Document Type: Article

References (30)

1. Blake BL, Rose RL, Mailman RB, Levi PE, and Hodgson E (1995) Metabolism of thioridazine by microsomal monooxygenases: relative roles of P450 and flavin-containing monooxygenase. Xenobiotica 25:377-393.
2. Cashman JR (1999) In vitro metabolism: FMO and related oxygenations, in Handbook of Drug Metabolism (Woolf TF ed) pp 477-505, Marcel Dekker, New York.
3. Chasseaud LF and Catanese B (1985) Pharmacokinetics of benzydamine. Int J Tissue React 7:195-204.
4. Eddershaw PJ, Beresford AP, and Bayliss MK (2000) ADME/PK as part of a rational approach to drug discovery. Drug Discov Today 5:409-414.
5. Eddershaw PJ and Dickins M (1999) Advances in in vitro drug metabolism screening. Drug Discov Today 2:13-19.
6. Ekins S, Ring BJ, Grace J, McRobie-Belle DJ, and Wrighton SA (2000) Present and future in vitro approaches for drug metabolism. J Pharmacol Toxicol Methods 44:313-324.
7. Grothusen A, Hardt J, Brautigam L, Lang D, and Bocker R (1996) A convenient method to discriminate between cytochrome P450 enzymes and flavin-containing monooxygenases in human liver microsomes. Arch Toxicol 71:64-71.
8. Haining RL, Hunter AP, Sadeque AJM, Philpot RM, and Rettie AE (1997) Baculovirus-mediated expression and purification of human FMO3: catalytic, immunochemical and structural characterization. Drug Metab Dispos 25:790-797.
9. Kalvass JC, Tess DA, Giragossian C, Linhares MC, and Maurer TS (2001) Influence of microsomal concentration on apparent intrinsic clearance: implications for scaling in vitro data. Drug Metab Dispos 29:1332-1336.
10. Kawaji A, Ohara K, and Takabatake E (1993) An assay of flavin-containing monooxygenase activity with benzydamine N-oxidation. Anal Biochem 214:409-412.
11. Kedderis GL and Rickert DE (1985) Loss of rat liver microsomal cytochrome P-450 during methimazole metabolism. Role of flavin-containing monooxygenase. Drug Metab Dispos 13:58-61.
12. Lang DH and Rettie AE (2000) In vitro evaluation of potential in vivo probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoforms. Br J Clin Pharmacol 50:311-314.
13. Lave T, Dupin S, Schmitt C, Chou RC, Jaeck D, and Coassolo P (1997) Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. J Pharm Sci 86:584-590.
14. Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, and Sugiyama Y (2001) Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 29:1316-1324.
15. Obach RS (2001) The prediction of human clearance from hepatic microsomal metabolism data. Curr Opin Drug Discov Devel 4:36-44.
16. Poulsen LL and Ziegler DM (1995) Multisubstrate flavin-containing monooxygenases: applications of mechanism to specificity. Chem-Biol Interact 96:57-73.
17. Ramanathan R, Su A-D, Alvarez N, Blumenkrantz N, Chowdhury SK, Alton K, and Patrick J (2000) Liquid chromatography/mass spectrometry methods for distinguishing N-oxides from hydroxylated compounds. Anal Chem 72:1352-1359.
18. Rettie AE, Meier GP, and Sadeque AJM (1995) Prochiral sulfides as in vitro probes for multiple forms of the flavin-containing monooxygenase. Chem-Biol Interact 96:3-15.
19. Ring BJ, Wrighton SA, Aldridge SLK, Hansen K, Haehner B, and Shipley LA (1999) Flavin-containing monooxygenase-mediated N-oxidation of the MI-muscarinic agonist xanomeline. Drug Metab Dispos 27:1099-1103.
20. Rodrigues AD (1994) Use of in vitro human metabolism studies in drug development: an industrial perspective. Biochem Pharmacol 48:2147-2156.
21. Rowland M and Tozer TN (1995) Clinical Pharmacokinetics: Concepts and Applications, 3rd ed., Williams and Wilkins, Media, PA.
22. Santi A, Anfossi P, Coldham NG, Capolongo F, Sauer MJ, and Montesissa C (2002) Biotransformation of benzydamine by microsomes and precision-cut slices prepared from cattle liver. Xenobiotica 32:73-86.
23. Schoenwald RD, Kumakura T, and Catanese B (1987) Pharmacokinetics of benzydamine. Int J Tissue React 9:93-97.
24. Shibata Y, Takahashi H, and Ishii Y (2000) A convenient in vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocytes suspended in serum. Drug Metab Dispos 28:1518-1523.
25. Soars MG, Burchell B, and Riley RJ (2002) In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 301:382-390.
26. Stormer E, Roots I. and Brockmoller J (2000) Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity. Br J Clin Pharmacol 50:553-561.
27. Thompson TN (2001) Optimization of metabolic stability as a goal of modem drug design. Med Res Rev 21:412-449.
28. Tong W, Chowdhury SK, Chen J-C, Zhong R, Alton KB, and Patrick JE (2001) Fragmentation of N-oxides (deoxygenation) in atmospheric pressure ionization: Investigations of the activation process. Rapid Commun Mass Spectrom 15:2085-2090.
29. Ubeaud G, Schiller CD, Hurbin F, Jaeck D, and Coassolo P (1999) Estimation of flavin-containing monooxygenase activity in intact hepatocyte monolayers of rat, hamster, rabbit, dog and human by using N-oxidation of benzydamine. Eur J Pharm Sci 8:255-260.
30. Venkatesh K, Blake B, Levi PE, and Hodgson E (1992) The flavin-containing monooxygenase in mouse lung: evidence for expression of multiple forms. J Biochem Toxicol 7:163-169.